moxifloxacin has been researched along with empagliflozin in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (empagliflozin) | Trials (empagliflozin) | Recent Studies (post-2010) (empagliflozin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,429 | 313 | 1,395 |
| Protein | Taxonomy | moxifloxacin (IC50) | empagliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0031 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brand, T; Breithaupt-Groegler, K; Broedl, UC; Macha, S; Ring, A; Simons, G; Walter, B; Woerle, HJ | 1 |
1 trial(s) available for moxifloxacin and empagliflozin
| Article | Year |
|---|---|
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
Topics: Action Potentials; Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Germany; Glucosides; Heart Conduction System; Heart Rate; Humans; Hypoglycemic Agents; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Young Adult | 2013 |